价值导向合同下的成本挤压，既是风险分配问题，也是报销问题。 医疗服务提供商面临特定困境——已对38,000名患者承担下行风险，却缺乏按 episode 定价所需的数据。在定价完成前，每 episode 成本会持续变动且无人能归因，关于投入成本转嫁的争论也将停留在意见层面。
价值导向合同下的成本挤压，既是风险分配问题，也是报销问题。 医疗服务提供商面临特定困境——已对38,000名患者承担下行风险，却缺乏按 episode 定价所需的数据。在定价完成前，每 episode 成本会持续变动且无人能归因，关于投入成本转嫁的争论也将停留在意见层面。
当每 episode 成本增速超过每归因患者收入时，第一反应往往是减少利用率或收紧内部流程。这值得做，但空间有限：你只能在单个 episode 内削减成本，而38,000名归因患者的 downside risk 仍在继续。
持久的应对是结构性的。重新谈判价值导向合同，将付款更新与公开的医疗成本指数挂钩，而非年度谈判。缩短合同期限，使重新定价在续约时发生。调整患者组合，在成本可转嫁的 payer 子集上提升贡献度。
另一半是 payer 组合。大多数面板的挤压并不均匀——部分合同允许成本转嫁，部分不允许——将归因患者转向前者，通常比在后者内部争取提价更快。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 每 episode 成本在上升，而价值导向合同下的归因患者数量保持稳定
✓ 每一次重大的报销变化都需要与 payer 重新谈判
✓ 价值导向合同不包含与外部成本指数挂钩的 escalation 机制
通常会让情况更糟的做法。 为保护面板规模而吸收更高的每 episode 成本，这会让 payer 习惯吸收，并使最终调整幅度更大。
It is for you if you run or finance a healthcare provider and gross margin is falling while volumes hold. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 成本与利润率改善, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
将其与外部可验证的指标挂钩，并提前通知。归因于公开指数的上涨是事实；归因于自身成本的上涨则是谈判邀请。
若存在可信指数，它能消除年度争论，通常在一个周期内即可收回成本。关键在于选择客户认可为中性的指数。
那就只能在续约时调整，期间的工作是优化组合和服务成本。同时也是修改合同的时机，因为同样的挤压还会重现。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית